A. Abdominal CT with intravenous contrast. B. Antithrombotic therapy. C. Follow-up ultrasound in 6 to 12 months. ... There is no indication for antithrombotic therapy in the treatment of this patient's aneurysm.
2. DS2-VASc score of 0, it is reasonable to use no antithrombotic therapy. ... a 77% multiple-procedure success rate with drug therapy, and a 52% success rate for drug therapy alone.
No antithrombotic therapy was prescribed in 102,229 patients (23.8%). Because researchers only used data from each patient's index visit, they conducted a sensitivity analysis and found that ... The median practice treatment prevalence with anticoagulant
Goldstein noted. Due to higher bleeding risk, combined antiplatelet-anticoagulant therapy is usually not recommended for stroke patients with atrial fibrillation. ... Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention
In patients being treated with antithrombotic therapy for ischemic cerebrovascular disease, individual decisions regarding periprocedural management of these medications need to weigh bleeding risks from drug continuation against thromboembolic risk
for major bleeding, both early and long-term, with triple therapy versus dual antiplatelet therapy. ... The goal of the study was to determine appropriate antithrombotic therapy in this population by comparing those taking DAPT with those taking triple
Higher CHADS2 scores pointed to higher risk for adverse outcomes, including stroke, bleeding and death, in patients with atrial fibrillation receiving anticoagulation, according to a new study.
Antithrombotic therapy for venous thromboembolism is another area where research continues to evolve, spurred in part by the advent of direct oral anticoagulants (DOACs), which came on the scene more than ... The drug class offers an attractive
There was no effect found when considering the variables of age, sex, socioeconomic status, major comorbidities, or therapy with antiplatelets or anticoagulants. ... statins. Other risks, such as history of intracerebral hemorrhage or use of
Outcomes were compared between the “resumed therapy” and “did not resume therapy” groups. ... Based on the available data, the editorialists wrote, “We believe that most patients with warfarin-associated GI bleeding and indications for